Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. / von Stemann, Jakob Hjorth; Gjærde, Lars Klingen; Haastrup, Eva Kannik; Minculescu, Lia; Brooks, Patrick Terrence; Sengeløv, Henrik; Hansen, Morten Bagge; Ostrowski, Sisse Rye.

In: Scientific Reports, Vol. 11, No. 1, 23971, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

von Stemann, JH, Gjærde, LK, Haastrup, EK, Minculescu, L, Brooks, PT, Sengeløv, H, Hansen, MB & Ostrowski, SR 2021, 'Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles', Scientific Reports, vol. 11, no. 1, 23971. https://doi.org/10.1038/s41598-021-01952-6

APA

von Stemann, J. H., Gjærde, L. K., Haastrup, E. K., Minculescu, L., Brooks, P. T., Sengeløv, H., Hansen, M. B., & Ostrowski, S. R. (2021). Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. Scientific Reports, 11(1), [23971]. https://doi.org/10.1038/s41598-021-01952-6

Vancouver

von Stemann JH, Gjærde LK, Haastrup EK, Minculescu L, Brooks PT, Sengeløv H et al. Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. Scientific Reports. 2021;11(1). 23971. https://doi.org/10.1038/s41598-021-01952-6

Author

von Stemann, Jakob Hjorth ; Gjærde, Lars Klingen ; Haastrup, Eva Kannik ; Minculescu, Lia ; Brooks, Patrick Terrence ; Sengeløv, Henrik ; Hansen, Morten Bagge ; Ostrowski, Sisse Rye. / Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles. In: Scientific Reports. 2021 ; Vol. 11, No. 1.

Bibtex

@article{ad06c26f7b674eacadd3daaceabfb243,

title = "Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles",

abstract = "Cytokine-specific autoantibodies (c-aAbs) represent an emerging field in endogenous immunodeficiencies, and the immunomodulatory potential of c-aAbs is now well documented. Here, we investigated the hypothesis that c-aAbs affects inflammatory, immunoregulatory and injury-related processes and hence the clinical outcome of haematopoietic stem cell transplantation (HSCT). C-aAbs against IL-1α, IL-6, IL-10, IFNα, IFNγ and GM-CSF were measured in 131 HSCT recipients before and after (days + 7, + 14, + 28) HSCT and tested for associations with 33 different plasma biomarkers, leukocyte subsets, platelets and clinical outcomes, including engraftment, GvHD and infections. We found that c-aAb levels were stable over the course of HSCT, including at high titres, with few individuals seeming to acquire high-titre levels of c-aAbs. Both patients with stable and those with acquired high-titre c-aAb levels displayed significant differences in biomarker concentrations and blood cell counts pre-HSCT and at day 28, and the trajectories of these variables varied over the course of HSCT. No clinical outcomes were associated with high-titre c-aAbs. In this first study of c-aAbs in HSCT patients, we demonstrated that high-titre levels of c-aAb may both persist and emerge in patients over the course of HSCT and may be associated with altered immune biomarkers and cell profiles.",

author = "{von Stemann}, {Jakob Hjorth} and Gj{\ae}rde, {Lars Klingen} and Haastrup, {Eva Kannik} and Lia Minculescu and Brooks, {Patrick Terrence} and Henrik Sengel{\o}v and Hansen, {Morten Bagge} and Ostrowski, {Sisse Rye}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

doi = "10.1038/s41598-021-01952-6",

language = "English",

volume = "11",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "nature publishing group",

number = "1",

}

RIS

TY - JOUR

T1 - Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles

AU - von Stemann, Jakob Hjorth

AU - Gjærde, Lars Klingen

AU - Haastrup, Eva Kannik

AU - Minculescu, Lia

AU - Brooks, Patrick Terrence

AU - Sengeløv, Henrik

AU - Hansen, Morten Bagge

AU - Ostrowski, Sisse Rye

PY - 2021

Y1 - 2021

N2 - Cytokine-specific autoantibodies (c-aAbs) represent an emerging field in endogenous immunodeficiencies, and the immunomodulatory potential of c-aAbs is now well documented. Here, we investigated the hypothesis that c-aAbs affects inflammatory, immunoregulatory and injury-related processes and hence the clinical outcome of haematopoietic stem cell transplantation (HSCT). C-aAbs against IL-1α, IL-6, IL-10, IFNα, IFNγ and GM-CSF were measured in 131 HSCT recipients before and after (days + 7, + 14, + 28) HSCT and tested for associations with 33 different plasma biomarkers, leukocyte subsets, platelets and clinical outcomes, including engraftment, GvHD and infections. We found that c-aAb levels were stable over the course of HSCT, including at high titres, with few individuals seeming to acquire high-titre levels of c-aAbs. Both patients with stable and those with acquired high-titre c-aAb levels displayed significant differences in biomarker concentrations and blood cell counts pre-HSCT and at day 28, and the trajectories of these variables varied over the course of HSCT. No clinical outcomes were associated with high-titre c-aAbs. In this first study of c-aAbs in HSCT patients, we demonstrated that high-titre levels of c-aAb may both persist and emerge in patients over the course of HSCT and may be associated with altered immune biomarkers and cell profiles.

AB - Cytokine-specific autoantibodies (c-aAbs) represent an emerging field in endogenous immunodeficiencies, and the immunomodulatory potential of c-aAbs is now well documented. Here, we investigated the hypothesis that c-aAbs affects inflammatory, immunoregulatory and injury-related processes and hence the clinical outcome of haematopoietic stem cell transplantation (HSCT). C-aAbs against IL-1α, IL-6, IL-10, IFNα, IFNγ and GM-CSF were measured in 131 HSCT recipients before and after (days + 7, + 14, + 28) HSCT and tested for associations with 33 different plasma biomarkers, leukocyte subsets, platelets and clinical outcomes, including engraftment, GvHD and infections. We found that c-aAb levels were stable over the course of HSCT, including at high titres, with few individuals seeming to acquire high-titre levels of c-aAbs. Both patients with stable and those with acquired high-titre c-aAb levels displayed significant differences in biomarker concentrations and blood cell counts pre-HSCT and at day 28, and the trajectories of these variables varied over the course of HSCT. No clinical outcomes were associated with high-titre c-aAbs. In this first study of c-aAbs in HSCT patients, we demonstrated that high-titre levels of c-aAb may both persist and emerge in patients over the course of HSCT and may be associated with altered immune biomarkers and cell profiles.

UR - http://www.scopus.com/inward/record.url?scp=85121287973&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-01952-6

DO - 10.1038/s41598-021-01952-6

M3 - Journal article

C2 - 34907183

AN - SCOPUS:85121287973

VL - 11

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 23971

ER -

ID: 305009425